Climb Bio Appoints Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy.

Climb Bio has appointed Adam Villa as SVP, Technical Operations, and Ashley Jones as SVP, People & Workforce Strategy. Villa has over 20 years of experience in biopharmaceutical development and manufacturing, while Jones has a proven record of building high-performing organizations and fostering cultures of collaboration and accountability. The appointments strengthen Climb Bio's leadership team as the company executes its clinical development plans and drives operational efficiency.

Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company focused on developing therapeutics for immune-mediated diseases, has announced significant leadership appointments to strengthen its operational capabilities. On October 21, 2025, the company welcomed Adam Villa as Senior Vice President, Technical Operations, and Ashley Jones as Senior Vice President, People & Workforce Strategy Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy^[1].

Adam Villa brings over two decades of experience in biopharmaceutical development and manufacturing, with a strong background in technical operations and scaling clinical production. He previously served as Vice President, CMC at Generation Bio, overseeing process and analytical development, technical operations, and Good Manufacturing Practice (GMP) supply initiatives. Villa's extensive experience includes leadership roles at CRISPR Therapeutics, Biogen, Genzyme, Wyeth Biopharma, and Amgen Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy^[1].

Ashley Jones is a seasoned people and culture leader with nearly 20 years of experience in the biotechnology sector. She has a proven track record of building high-performing, mission-driven organizations. Jones previously led people and operations functions at Ananke Therapeutics, Imara, and SQZ Biotechnologies, and performed various human resources roles at Vertex Pharmaceuticals. She also founded and led Cultivate Co., a consulting practice providing fractional human resources support to emerging private and public biotechnology companies Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy^[1].

These appointments come at a critical juncture for Climb Bio, as the company executes its clinical development plans for budoprutug and CLYM116, an anti-APRIL monoclonal antibody being developed for IgA nephropathy. The additions of Villa and Jones aim to enhance operational efficiency and drive excellence in both technical operations and workforce strategy Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy^[1].

In connection with these appointments, Climb Bio granted each new executive an inducement equity award, consisting of non-statutory stock options to purchase up to an aggregate of 360,000 shares of common stock. The options have an exercise price of $2.32 per share, a ten-year term, and vest over four years, with 25% vesting on the first anniversary of employment and the remainder vesting in 36 equal monthly installments thereafter Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy^[1].

These strategic hires underscore Climb Bio's commitment to advancing its pipeline and maintaining its competitive edge in the biotechnology sector. As the company continues to develop innovative treatments for immune-mediated diseases, the appointments of Villa and Jones position Climb Bio for sustained growth and operational success.